Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3182.

https://doi.org/10.1182/blood-2019-128749

Published: 2019

Journal Articles

Hematologist Experiences and Perceptions of Outpatient Management of Adult Patients with Sickle Cell Disease

Jennifer Yui, MD, Farzana Sayani, MD, Marilyn Schapira, MD

Blood (2019) 134 (Supplement_1): 4710.

https://doi.org/10.1182/blood-2019-131611

Published: 2019

Journal Articles

Does Race Impact Survival in Multiple Myeloma?

Elizabeth Kennedy-LeJeune, MD, Hollis O'Neal, MD MSc, Lauren Miles, MD, Diana Hamer, PhD, Vince D. Cataldo, MD

Blood (2018) 132 (Supplement 1): 5580.

https://doi.org/10.1182/blood-2018-99-116760

Published: 2018

Journal Articles

Urinary Cross-Linked Carboxyterminal Telopeptide Decreases with Resolution of Painful Vaso-Occlusive Crises in Adults with Sickle Cell Disease - Results from the Sickle Cell Pain Markers (SCPM) Study

Oyebimpe O. Adesina, MD, Isaac C. Jenkins, MS, Qian V. Wu, PhD, Ellen B. Fung, PhD RD, CCD, Kanika Mahajan, Rebecca Kruse-Jarres, MDMPH

Blood (2018) 132 (Supplement 1): 1100.

https://doi.org/10.1182/blood-2018-99-119801

Published: 2018

Journal Articles

Population Level Survival for Patients with Multiple Myeloma By Insurance Type and Early Indications of Changes with Adoption of the Medicaid Expansion of the Affordable Care Act

Dianne Pulte, MD, Lina Jansen, PhD, Janick Weberpals, Hermann Brenner, MD MPH

Blood (2017) 130 (Supplement 1): 3438.

https://doi.org/10.1182/blood.V130.Suppl_1.3438.3438

Published: 2017

Journal Articles

Availability of ATRA, Blood BANK Support, Treatment Protocols and Hematologists/Oncologists for Management of APL in Two States (MICHIGAN AND LOUSIANA)

Sheldon Bolds, Shruthi M.K Hassan, Catherine R. Caprara, MSN, NP, Stephanie Debragga, Kathryn Sarah Simon, PA-C, Prachi Kharkhanis, Arpita Gandhi, Martha L. Arellano, MD, Anand Jillella, MD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 5620.

https://doi.org/10.1182/blood.V130.Suppl_1.5620.5620

Published: 2017

Journal Articles

Targeting MALT1 with the Small Molecule Inhibitor MI2 Induces a Caspase-Dependent Apoptosis and Inhibits the NF-κb Pathway in Chronic Lymphocytic Leukemia Primary Cells

Georges Tanios, MD, Patricia Lobelle-Rich, Ashwin Vasudevamurthy, MD, Thomas S. Atkinson, MD, Ali Baghian, MD, Delong Liu, PhD, Hana Safah, MD, Erik K. Flemington, PhD, Nakhle S. Saba, MD

Blood (2016) 128 (22): 1597.

https://doi.org/10.1182/blood.V128.22.1597.1597

Published: 2016

Journal Articles

Prevalence of Disease Related Complications from in Adult Patients with Sickle Cell Disease

Samip Master, MD, Shajadi Patan, MD, Shashank Cingam, MD, Richard Preston Mansour, MD

Blood (2016) 128 (22): 4862.

https://doi.org/10.1182/blood.V128.22.4862.4862

Published: 2016

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplantation Using Melphalan and Total Body Irradiation Conditioning in Multiple Myeloma

Ali Baghian, MD, Reinhold Munker, MD, Yordanka Koleva, MPH, Gunita Matharoo, MPH, Patricia Andrews, MPH, Ato Wright, MD PhD, Nakhle S. Saba, MD, Hana Safah, MD

Blood (2016) 128 (22): 4644.

https://doi.org/10.1182/blood.V128.22.4644.4644

Published: 2016

Journal Articles

Insurance Status, Marital Status and Income, but Not Race-Ethnicity Affect Outcomes of Younger Patients Diagnosed with Multiple Myeloma in the US

Luciano J Costa, MD PhD, Elizabeth E. Brown, PhD MPH

Blood (2015) 126 (23): 633.

https://doi.org/10.1182/blood.V126.23.633.633

Published: 2015

Journal Articles

Population Outcomes Of Primary Mediastinal Large B-Cell Lymphoma In The Rituximab Era

Karen Ortiz Cruz, MD, Luciano J. Costa, MD, PhD

Blood (2013) 122 (21): 1743.

https://doi.org/10.1182/blood.V122.21.1743.1743

Published: 2013

Journal Articles

Outpatient Visits, Hospitalizations and Emergency Department Visits Among Patients with Sickle Cell Disease On Medicaid: Trends in 14 USA States, 2006–2007.

Benjamin Ansa, MD, Tom Adamkiewicz, MD, MSCR, FRCP(C), Yvonne Fry-Johnson, MD, MSCR, Gregory Strayhorn, MD, PhD, Barbara Moore, George S Rust, MD, MPH

Blood (2012) 120 (21): 3181.

https://doi.org/10.1182/blood.V120.21.3181.3181

Published: 2012

Journal Articles

Impact of Health Care Funding on overall Survival of Patients with Multiple Myeloma and Monoclonal Gammopathy of Uncertain Significance.

Srinivas S Devarakonda, MD, Binu S. Nair, MD, Ryan A. Gonzales, MD, Runhua Shi, MD, PhD, Nebu Koshy, MD, Gary Burton, MD, Jonathan Glass, MD, Francesco Turturro, MD

Blood (2010) 116 (21): 3821.

https://doi.org/10.1182/blood.V116.21.3821.3821

Published: 2010

Journal Articles

Bone Marrow Myeloid-Derived Suppressor Cells (MDSC) Inhibit Graft Versus Host Disease (GVHD) Via An Arginase-1 Dependant Mechanism That Is Upregulated by IL-13

Steven L Highfill, PhD, Paulo Rodriguez, PhD, Qing Zhou, PhD, Christine A Goetz, PhD, Rachelle Veenstra, Patricia A Taylor, DVM, Angela Panoskaltsis-Mortari, PhD, Jonathan Serody, MD, David Munn, Jakub Tolar, MD, PhD, Augusto C Ochoa, MD, Bruce R. Blazar, MD

Blood (2010) 116 (21): 241.

https://doi.org/10.1182/blood.V116.21.241.241

Published: 2010

Journal Articles

Monitoring Immune Function by the Cylex Immuknow Assay in Pediatric HSCT Patients.

Lolie C. Yu, MD, Judy Britz, PhD, Martha Martin, Richard Kowalski, PhD

Blood (2006) 108 (11): 5312.

https://doi.org/10.1182/blood.V108.11.5312.5312

Published: 2006

Journal Articles

A high bone marrow plasma cell labeling index in stable plateau–phase multiple myeloma is a marker for early disease progression and death: Presented in abstract form at the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, May 20-23, 2000.

David P. Steensma, Morie A. Gertz, Philip R. Greipp, Robert A. Kyle, Martha Q. Lacy, John A. Lust, Janice R. Offord, Matthew F. Plevak, Terry M. Therneau, Thomas E. Witzig

Blood (2001) 97 (8): 2522–2523.

https://doi.org/10.1182/blood.V97.8.2522

Published: 2001

NARROW

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Hematologist Experiences and Perceptions of Outpatient Management of Adult Patients with Sickle Cell Disease

Does Race Impact Survival in Multiple Myeloma?

Urinary Cross-Linked Carboxyterminal Telopeptide Decreases with Resolution of Painful Vaso-Occlusive Crises in Adults with Sickle Cell Disease - Results from the Sickle Cell Pain Markers (SCPM) Study

Population Level Survival for Patients with Multiple Myeloma By Insurance Type and Early Indications of Changes with Adoption of the Medicaid Expansion of the Affordable Care Act

Availability of ATRA, Blood BANK Support, Treatment Protocols and Hematologists/Oncologists for Management of APL in Two States (MICHIGAN AND LOUSIANA)

Targeting MALT1 with the Small Molecule Inhibitor MI2 Induces a Caspase-Dependent Apoptosis and Inhibits the NF-κb Pathway in Chronic Lymphocytic Leukemia Primary Cells

Prevalence of Disease Related Complications from in Adult Patients with Sickle Cell Disease

Long-Term Outcomes of Autologous Hematopoietic Cell Transplantation Using Melphalan and Total Body Irradiation Conditioning in Multiple Myeloma

Insurance Status, Marital Status and Income, but Not Race-Ethnicity Affect Outcomes of Younger Patients Diagnosed with Multiple Myeloma in the US

Population Outcomes Of Primary Mediastinal Large B-Cell Lymphoma In The Rituximab Era

Outpatient Visits, Hospitalizations and Emergency Department Visits Among Patients with Sickle Cell Disease On Medicaid: Trends in 14 USA States, 2006–2007.

Impact of Health Care Funding on overall Survival of Patients with Multiple Myeloma and Monoclonal Gammopathy of Uncertain Significance.

Bone Marrow Myeloid-Derived Suppressor Cells (MDSC) Inhibit Graft Versus Host Disease (GVHD) Via An Arginase-1 Dependant Mechanism That Is Upregulated by IL-13

Monitoring Immune Function by the Cylex Immuknow Assay in Pediatric HSCT Patients.

A high bone marrow plasma cell labeling index in stable plateau–phase multiple myeloma is a marker for early disease progression and death: Presented in abstract form at the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, May 20-23, 2000.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only